Light chain deposition disease with liver dysfunction
Pierre Bédossa(Régie Autonome des Transports Parisiens (France)), G Lemaigre(Institute of Oriental Manuscripts), E. Martin(Institut de Cancérologie de l'Ouest), François Paraf, Aurélie Fabre(St. Vincent's University Hospital)
Cited by 23
Related Papers
NASH limits anti-tumour surveillance in immunotherapy-treated HCC
|Nature|2021|1.3k
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
|The Lancet|2019|1.2k
Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
|Gastroenterology|2016|1k
Guidelines for autopsy investigation of sudden cardiac death: 2017 update from the Association for European Cardiovascular Pathology
|Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin|2017|538